Parenteral drug use as the main barrier to hepatitis C treatment uptake in HIV-infected patients.

Antonio RiveroF TellezM Castaño-CarracedoD MerinoN EspinosaJ SantosJ MaciasM Paniagua-GarcíaA Zapata-LopezA ColladoM A Gómez-VidalJavier Perez StachowskiL Muñoz-MedinaE Fernandez-FuertesA Riveronull null

Published in: HIV medicine (2019)

We identified factors, which did not include prioritization of a DAA uptake strategy, that limited access to HCV therapy. The low treatment uptake in several populations seriously jeopardizes the elimination of HCV infection in the coming years.

Keyphrases

hiv infected patients
hepatitis c virus
antiretroviral therapy
human immunodeficiency virus
mesenchymal stem cells
bone marrow
hiv infected